Cyclacel pharmaceuticals, inc. (CYCC)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Jun'10
Revenues:
Total revenues

-

-

-

150

-

150

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration and research and development revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

843

990

1,247

1,321

1,694

1,517

1,790

1,850

1,734

1,786

1,360

1,268

1,084

823

540

0

-

0

0

-

-

Collaboration and research and development revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

-

1,850

1,734

1,786

1,360

1,268

1,084

823

540

0

-

0

0

-

0

Operating expenses:
Cost of goods sold

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Research and development

4,752

4,658

4,370

4,512

4,541

4,327

3,930

3,683

3,723

4,237

5,424

6,875

8,290

9,477

10,101

10,596

10,539

12,382

14,242

16,310

18,275

18,277

16,352

15,955

14,041

11,277

10,782

7,739

6,825

6,592

0

0

0

0

General and administrative

5,150

5,024

5,135

5,100

5,199

5,371

5,349

5,253

5,237

5,254

5,316

5,435

5,513

5,516

5,728

5,660

5,648

5,732

5,619

5,847

5,900

5,894

6,063

6,159

6,560

7,781

8,662

9,161

9,495

8,580

0

0

0

0

Total operating expenses

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

24,175

24,171

22,415

22,114

20,601

19,058

19,444

16,900

16,320

15,172

0

0

0

0

Total operating expenses

-

-

-

9,612

-

-

-

8,936

8,960

9,491

0

0

0

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating loss

-9,902

-9,682

-9,355

-9,462

-9,590

-9,548

-9,279

-8,936

-8,960

-9,491

-10,463

-11,828

-13,099

-14,150

-14,842

-14,759

-14,616

-16,170

-18,091

-20,367

-22,325

-22,437

-20,629

-20,754

-19,333

-17,974

-18,654

-16,381

-16,039

-15,103

0

0

0

0

Other income (expense):
Change in valuation of financial instruments associated with stock purchase agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

278

255

315

342

0

0

0

-

-

0

-

-

-

-

-

-

Change in valuation of Economic Rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-570

-520

-457

-603

23

0

0

0

-

Change in valuation of liabilities measured at fair value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

51

0

0

0

-

Change in valuation of warrants liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Foreign exchange gains (losses)

155

101

67

-11

-71

-90

-16

-39

16

-39

-161

-88

34

273

355

523

190

-368

-341

-550

-398

-10

-5

10

-48

62

99

80

298

292

0

0

0

0

Interest income

173

224

270

313

341

331

296

241

175

118

66

44

39

37

35

29

18

9

6

7

6

6

6

11

13

13

17

14

17

22

0

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other income, net

0

-

0

0

-

682

674

702

636

949

917

907

925

66

55

50

94

94

121

0

0

-

-

0

-

5,547

5,520

5,505

34

77

0

0

0

-

Total other income, net

1,376

556

610

522

386

923

954

904

827

1,028

822

863

998

376

445

575

271

-316

-430

-628

-553

-212

-139

-99

5,363

6,094

5,733

5,634

538

-4

0

0

0

0

Loss before taxes

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,878

-22,649

-20,768

-20,853

-13,970

-11,880

-12,921

-10,747

-15,501

-15,107

0

0

0

0

Loss before taxes

-

-

-

0

-

-

-

0

0

-

0

0

0

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-1,318

-1,296

-1,200

-1,228

-1,423

-1,337

-1,185

-1,103

-869

-993

-1,203

-1,438

-1,796

-1,983

-2,071

-2,095

-1,874

-2,144

-2,754

-3,026

-3,437

-3,243

-2,587

-2,567

-1,981

-1,670

-1,855

-1,544

-1,441

-1,351

0

0

0

0

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19,406

-18,181

-18,286

-11,989

-10,210

-11,066

-9,203

-14,060

-13,756

0

0

0

-

Income from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

50

64

78

91

1,333

1,115

0

-

0

0

-

-

Income tax on discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

16

22

29

34

0

0

0

-

-

-

-

-

Net income from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19

34

42

49

57

-292

959

747

570

0

0

0

-

Net loss

-7,208

-7,830

-7,545

-7,712

-7,781

-7,288

-7,140

-6,929

-7,264

-7,470

-8,438

-9,527

-10,305

-11,791

-12,326

-12,089

-12,471

-14,342

-15,767

-17,965

-19,430

-19,387

-18,147

-18,244

-11,940

-10,153

-11,358

-8,244

-13,313

-13,186

0

0

0

0

Dividend on convertible exchangeable preferred shares

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividend on convertible exchangeable preferred shares

-

-

-

0

-

-

-

0

0

-

200

200

200

200

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Beneficial conversion feature of Series A convertible stock

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss applicable to common shareholders

-7,409

-8,031

-7,746

-7,913

-7,982

-7,489

-7,505

-14,305

-14,640

-14,846

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend on convertible exchangeable preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,027

0

0

0

-

-

-

-

0

Dividend on convertible exchangeable preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

200

200

213

226

298

430

549

668

728

0

0

0

0

Net loss applicable to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,290

-12,672

-14,543

-15,967

-18,165

-19,630

-19,587

-18,347

-19,118

-12,827

-19,478

-20,815

-17,159

-22,347

-13,914

0

0

0

0

Basic and diluted earnings per common share:
Net loss per share, continuing operations - basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.20

-0.22

-0.22

-0.25

-

-0.32

-

-1.18

-

-0.40

-

-0.38

-

Net income per share, discontinued operations - basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

0.15

-

-0.02

-

Net income per share, discontinued operations - basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

0.00

0.00

-

0.00

-

-

-

-

-

-

-

Net loss per share - basic and diluted (in dollars per share)

-1.48

2.50

-0.11

-0.11

-2.77

-0.16

-0.18

-0.16

-0.12

-0.16

-0.91

-0.50

-0.38

-0.59

-0.86

-1.01

-1.04

-3.03

-0.95

-1.19

-0.19

-0.20

-0.22

-0.22

-0.25

-

-0.32

-

-1.18

-

-0.25

-

-0.40

-

Weighted average common shares outstanding - basic and diluted

859

30,205

17,199

17,199

681

12,384

11,997

11,997

11,997

11,983

9,835

4,434

4,271

4,260

3,473

3,000

2,965

-20,970

2,889

2,865

26,067

23,032

22,676

22,582

19,530

-

17,788

-

-

-

-

-

-

-

Net income (loss) per share, continuing operations (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-0.42

-

-

Net income (loss) per share, discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

Net (loss) income per share, discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.02

-

-

Net income (loss) per share applicable to common shareholders (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-0.45

-

-0.18

Net income (loss) per share, continuing operations - Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-0.42

-

-

Net income (loss) per share, discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

Net (loss) income per share, discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.02

-

-

Net income (loss) per share applicable to common shareholders (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-0.45

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,885

9,790

8,486

8,429

8,428

7,823

36,565

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,927

-

-

-

8,428

-

-